Hepatocyte transplantation: State of the art

Galvão, Flávio Henrique Ferreira; Júnior, Dahir Ramos de Andrade; Andrade, Dahir Ramos de; Martins, Bruno Costa; Marson, Allan Garms; Bernard, Christiano Vinicius; Santos, Sânia Alves dos; Bacchella, Telésforo; Machado, Marcel Cerqueira César

doi:10.1016/j.hepres.2006.08.008

Cited by 13 publications

(10 citation statements)

References 81 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There are a few case reports concerning the more simple technique of liver cell transplantation (LCTX) [16] as a treatment for ALF. LCTX has at least 2 important drawbacks: (1) the availability of sufficient amounts of fully differentiated human liver cells; (2) the so far unsolved problem of transplanting large amounts (at least 10% of the normal parenchymal mass) of cells where there is adequate blood supply.…”

Section: Critical Issuesmentioning

confidence: 99%

Future of bioartificial liver support

Chamuleau¹

2009

WJGS

View full text Add to dashboard Cite

Many different artificial liver support systems (biological and non-biological) have been developed, tested preclinically and some have been applied in clinical trials. Based on theoretical considerations a biological artificial liver (BAL) should be preferred above the non-biological ones. However, clinical application of the BAL is still experimental. Here we try to analyze which hurdles have to be taken before the BAL will become standard equipment in the intensive care unit for patients with acute liver failure or acute deterioration of chronic liver disease.

show abstract

Section: Critical Issuesmentioning

confidence: 99%

Future of bioartificial liver support

Chamuleau¹

2009

WJGS

View full text Add to dashboard Cite

show abstract

“…Human hepatocytes are the key functional components and bottleneck in the development of alternative less-invasive approaches to treat liver failure. Billions of hepatocytes are required per hepatocyte transplant (15,18,48), drug discovery and development (20,21), bioartificial liver assist device (BAL) treatment (7,10,53), and recellularization of tissue engineered scaffolds (61). Inadequate yields from suboptimal livers average 1–17 million cells per gram liver (approximately 10 10 cells for a 1500g liver), driving prices to $165 per million cells, while the variability in liver quality dramatically impacts cell performance (5,6,59,60,69).…”

Section: Introductionmentioning

confidence: 99%

Simple Machine Perfusion Significantly Enhances Hepatocyte Yields of Ischemic and Fresh Rat Livers

et al. 2013

View full text Add to dashboard Cite

The scarcity of viable hepatocytes is a significant bottleneck in cell transplantation, drug discovery, toxicology, tissue engineering, and bioartificial assist devices, where trillions of high-functioning hepatocytes are needed annually. We took the novel approach of using machine perfusion to maximize cell recovery, specifically from uncontrolled cardiac death donors, the largest source of disqualified donor organs. In a rat model, we developed a simple 3 hour room temperature (20±2°C) machine perfusion protocol to treat non-premedicated livers exposed to 1 hour of warm (34°C) ischemia. Treated ischemic livers were compared to fresh, fresh-treated and untreated ischemic livers using viable hepatocyte yields and in vitro performance as quantitative endpoints. Perfusion treatment resulted in both a 25-fold increase in viable hepatocytes from ischemic livers, and a 40% increase from fresh livers. While cell morphology and function in suspension and plate cultures of untreated warm ischemic cells was significantly impaired, treated warm ischemic cells were indistinguishable from fresh hepatocytes. Further, a strong linear correlation between tissue ATP and cell yield enabled accurate evaluation of the extent of perfusion recovery. Maximal recovery of warm ischemic liver ATP content appears to be correlated with optimal flow through the microvasculature. These data demonstrate that the inclusion of a simple perfusion-preconditioning step can significantly increase the efficiency of functional hepatocyte yields and the number of donor livers that can be gainfully utilized.

show abstract

“…Organ shortage has impaired transplantation activity and caused increases in waiting list mortality everywhere. Recently, hepatocyte transplantation and living donor liver transplantation (LDLT) have emerged as promising methods to treat liver disease 1 . LDLT is an effective method to cure terminal liver disease.…”

Section: Introductionmentioning

confidence: 99%

“…Recently, hepatocyte transplantation and living donor liver transplantation (LDLT) have emerged as promising methods to treat liver disease. 1 LDLT is an effective method to cure terminal liver disease. A right lobe graft without drainage of the MHV is controversial, but we believe it is a safe operation.…”

Section: Introductionmentioning

confidence: 99%

Hepatic venous outflow reconstruction in right lobe graft without middle hepatic vein

Yan

et al. 2007

Hepatology Research

View full text Add to dashboard Cite

Graft function and survival rates are not only influenced by graft size, but also by hepatic venous outflow reconstruction; the 'multiple-opening vertical anastomosis' for reconstruction of hepatic vein outflow was used when the GRWR was smaller than 1.2%. This technique alleviates surgical risk in living donors, ensures excellent venous drainage, and reduces the incidence of small-for-size syndrome.

show abstract

Hepatocyte transplantation: State of the art

Cited by 13 publications

References 81 publications

Future of bioartificial liver support

Future of bioartificial liver support

Simple Machine Perfusion Significantly Enhances Hepatocyte Yields of Ischemic and Fresh Rat Livers

Hepatic venous outflow reconstruction in right lobe graft without middle hepatic vein

Contact Info

Product

Resources

About